pharma · high blood pressure · increased blood clotting
APREMEDA s.r.o
s.r.o.
s.r.o is a pharma organization headquartered in EU. Primary therapeutic focus areas include high blood pressure, increased blood clotting, Stable Ischemic Heart Disease. NovaPharmaNews links 5 clinical program(s), 0 drug
EU HQ
2020 Founded
18 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Founded
- 2020
- Employees
- 18
- Programs
- 5
- Drugs
- 16
- Patents
- 0
01/2023/Pozlab
Phase 1 · other · increased blood clotting
01/2023/Pozlab for increased blood clotting is a Phase 1 program (other) at s.r.o. with 1 ClinicalTrials.gov record(s).
Internal code 01/2023/Pozlab
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- s.r.o.
- Phase
- Phase 1
- Modality
- other
- Indication
- increased blood clotting
- Status
- active
- Trials
- 1